Chick-fil-A has relaunched its iconic football-shaped trays in the wake of the football season. These trays were launched on September 4, 2024, but will soon exit the market by February 8, 2025. They ...

Ustekinumab biosimilar is under clinical development by Celltrion and currently in Pre-Registration for Psoriatic Arthritis. According to GlobalData, Pre-Registration drugs for Psoriatic Arthritis ...

Will the Stelara biosimilars be a reprise of the Humira biosimilars in 2023 and be slow to catch on? Biosimilar watchers circled 2023 as a red-letter year because that was the year that the Humira ...

While speaking at the conference, J&J’s CEO, Joaquin Duato, indicated the company’s willingness to protect Stelara, its branded anti-interleukin (IL)-12/23 biologic, against sales erosion from ...

Vigorous protection of Stelara’s position aligns with a strategy to grow in the immunology space. Credit: josefkubes via Shutterstock. During its presentation at the JP Morgan Healthcare Conference ...

Formycon (FSE: FYB) and its commercialization partner, fellow German firm Fresenius Kabi, have received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Otulfi ...

Stelara (ustekinumab) is a prescription drug that treats autoimmune conditions such as plaque psoriasis. You typically inject it subcutaneously (under your skin) or receive it intravenously ...

Stelara (ustekinumab) is a brand-name injectable drug prescribed for certain autoimmune conditions. Stelara has interactions with some other drugs and certain vaccines. Examples include Orencia ...

No clinically meaningful differences were observed in the efficacy, safety, pharmacokinetics, and immunogenicity of proposed biosimilar and ustekinumab for the treatment of moderate to severe plaque ...

TORONTO, Jan. 8, 2025 /CNW/ - Fresenius Kabi Canada proudly announces the recent Health Canada Notice of Compliance (NOC) for Otulfi TM, an ustekinumab biosimilar indicated for Crohn's disease ...

On Dec 24, 2024, Bio-Thera Solutions Inc. announced that it has partnered with Tabuk Pharmaceutical Manufacturing Company to commercialize BAT2206, a proposed ustekinumab biosimilar to Jansen’s ...